YAP1 and pulmonary arterial hypertension: The inhibition of GLS1 in some clinical trials using cancer drugs (NCT02071862) (82), NMDAR using MK-801(43), and YAP using verteporfin (34) has proven to be beneficial in ameliorating PAH progression.